NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03707509,Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma,https://clinicaltrials.gov/study/NCT03707509,,UNKNOWN,"This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study. Target population is patients with recurrent/metastatic nasopharyngeal carcinoma who had not received systemic chemotherapy. Study objective is to compare the efficacy and safety of camrelizumab in combination with gemcitabine and cisplatin with placebo in combination with gemcitabine and cisplatin in study population in China. camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.",NO,Nasopharyngeal Carcinoma,DRUG: Camrelizumab|DRUG: Placebos|DRUG: Gemcitabine|DRUG: Cisplatin,"Progression-free survival (PFS), PFS, defined as the time from randomization to the first occurrence of disease progression as determined by the Independent Review Committee according to RECIST v1.1 or death from any cause, whichever occurs first., up to 24 month","Progression-free survival, Progression-free survival (PFS) assessed by investigators according to RECIST V 1.1, up to 24 month|Objective Response Rate (ORR), The percentage of patients with CR and PR assessed by investigators according to Recist v 1.1, up to 24 month|Disease Control Rate (DCR) Disease Control Rate (DCR), The proportion of patients who have achieved complete responseï¼Œ partial response and Stable disease assessed by investigators according to Recist v 1.1, up to 24 month|Duration of Response (DoR), According to Recist v 1.1 accessed by investigators, up to 24 month|2 years Overall Survival (OS) rate, The percentage of patients overall survival in 2 years, up to 24 month|Adverse Events (AEs), All adverse event/Serious adverse event that occurred during the study period according to CTCAE v 4.03, up to 24 month","Antidrug Antibodies (ADAs), To evaluate the incidence and titers of ADAs against camrelizumab, up to 24 month","Jiangsu HengRui Medicine Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,263,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",SHR-1210-III-308,2018-11-13,2021-08-01,2022-12-31,2018-10-16,,2022-07-01,"Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, 510060, China",
